LOGIN  |  REGISTER

Butterfly Network to Report First Quarter 2023 Financial Results on May 11, 2023

April 27, 2023 | Last Trade: US$2.97 0.15 -4.81

BURLINGTON, Mass. & NEW YORK / Apr 27, 2023 / Business Wire / Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”), a digital health company transforming care with handheld, whole-body ultrasound, announced that it will report first quarter 2023 financial results and provide a business update on May 11, 2023, before the market opens.

Joseph DeVivo, President, Chief Executive Officer, and Chairman of the Board; Heather Getz, Executive Vice President and Chief Financial Officer; and Darius Shahida, Chief Strategy Officer, will host a conference call and webcast at 8:30 am ET on May 11, 2023 to discuss first quarter 2023 financial results and operational progress.

The conference call will be broadcast live in listen-only mode via a webcast on Butterfly’s Investor Relations website at Events & Presentations.

Individuals interested in listening to the conference call on your telephone may do so by dialing approximately ten minutes prior to start time:

United States: 1 (833) 470 1428
Global Dial-In Numbers: https://www.netroadshow.com/events/global-numbers?confId=49034
Access Code: 669966

After the live webcast, the call will be archived on Butterfly’s Investor Relations page.
In addition, a telephone replay of the call will be available until May 25, 2023, by dialing:

United States: 1 (866) 813 9403
Canada: 1 (226) 828 7578
All other locations: +44 204 525 0658
Access Code: 606818

About Butterfly Network, Inc.

Founded by Dr. Jonathan Rothberg in 2011 and listed on the New York Stock Exchange through a business combination with Longview Acquisition Corp., Butterfly created the world's first handheld, single probe whole-body ultrasound system using semiconductor technology, the Butterfly iQ+. Butterfly's mission is to democratize medical imaging and contribute to the aspiration of global health equity, making high-quality ultrasound affordable, easy-to-use, globally accessible, and intelligently connected, including for the 4.7 billion people around the world lacking access to ultrasound. Through its proprietary Ultrasound-on-Chip™ technology, Butterfly is paving the way for earlier detection and remote management of health conditions around the world. The Butterfly iQ+ can be purchased today by trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, Australia, Europe, North America and South America; to learn more about available countries, visit: butterflynetwork.com/choose-your-country. Butterfly iQ+ is a prescription device intended for qualified healthcare professionals only. For more information, visit www.butterflynetwork.com.

C4 Therapeutics

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB